UNII 70WT22SF4B

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

Unique Ingredient Identifier 70WT22SF4B is listed as a ingredient substance
Unii70WT22SF4B
Preferred Substance NameSODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
Rn7782-85-6
NcitC61946
Rxcui221090
Pubchem6096963
Molecular Formula2Na.HO4P.7H2O
InchikeyPYLIXCKOHOHGKQ-UHFFFAOYSA-L
SmilesO.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O
Unii TypeINGREDIENT SUBSTANCE
RN7782-85-6
NCITC61946
RXCUI221090
PUBCHEM6096963
MF2Na.HO4P.7H2O
INCHI KEYPYLIXCKOHOHGKQ-UHFFFAOYSA-L
SMILESO.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O

Alternate Names

Dosage Forms

UNII 70WT22SF4B SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE is commonly included in medications in the following forms.

RouteDosage FormPotency
AN,INFILTRATIONINJECTION0.02 %
AURICULAR (OTIC)SOLUTION0.5 %
AURICULAR (OTIC)SUSPENSION NA
IM - IVINJECTION20 %
IM - IVPOWDER27.93 %
IM - IVPOWDER, FOR INJECTION SOLUTION8 %
IM - IVSOLUTION, INJECTION0.57 %
IM - IV - SCINJECTION1.35 MG/ML
IM - SCINJECTION0.027 %
IM - SCPOWDER, FOR INJECTION SOLUTION NA
INTRA-ARTICULARINJECTABLE0.3 %W/W
INTRA-ARTICULARINJECTION ADJPH
INTRA-ARTICULARSUSPENSION0.35 %
INTRABURSALINJECTION1.35 MG/ML
INTRABURSALINJECTION ADJPH
INTRADERMALINJECTION NA
INTRALESIONALINJECTABLE0.14 %
INTRALESIONALINJECTION1.35 MG/ML
INTRALESIONALINJECTION, SUSTAINED ACTION1.35 MG/ML
INTRAMUSCULARINJECTABLE0.3 %W/W
INTRAMUSCULARINJECTION NA
INTRAMUSCULARINJECTION, SUSTAINED ACTION0.067 %W/V
INTRAMUSCULARPOWDER, FOR INJECTION SOLUTION0.54 %
INTRAMUSCULARPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED21.5 %
INTRAMUSCULARPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED, WITH 0.37 %
INTRAMUSCULARSOLUTION, INJECTION NA
INTRAMUSCULARSUSPENSION0.35 %
INTRASYNOVIALINJECTABLE0.14 %
INTRASYNOVIALINJECTION, SUSTAINED ACTION1.35 MG/ML
INTRAVENOUSINJECTABLE14.4 mg/mL
INTRAVENOUSINJECTABLE0.094 %
INTRAVENOUSINJECTION1.44 %
INTRAVENOUSPOWDER, FOR INJECTION SOLUTION2.9 %
INTRAVENOUSSOLUTION, INJECTION1.44 %
INTRAVITREALINJECTABLE1.33 %
IV(INFUSION)INJECTION1.23 %
IV(INFUSION)POWDER, FOR INJECTION SOLUTION2 %
IV(INFUSION)POWDER, FOR INJECTION SOLUTION, LYOPHILIZED21.5 %
NASALSOLUTION0.045 %
NASALSOLUTION, SPRAY, METERED, PUMP0.066 %
NASALSPRAY, METERED0.49 %
NERVE BLOCKINJECTION0.02 %
OPHTHALMICDROPS0.36 %
OPHTHALMICSOLUTION2.76 mg/1mL
OPHTHALMICSOLUTION2.15 %
OPHTHALMICSOLUTION, DROPS2.5 %
OPHTHALMICSOLUTION/DROPS0.55 %
OPHTHALMICSUSPENSION0.87 %
OPHTHALMICSUSPENSION, DROPS0.43 %
ORALCAPSULE500 MG
ORALCAPSULE, SUSTAINED ACTION92 MG
ORALDROPS NA
ORALSOLUTION70.5 MG/5ML
ORALSUSPENSION62.5 MG/5ML
ORALSYRUP0.65 MG/1ML
ORALTABLET80 MG
ORALTABLET, COATED0.22 MG
ORALTABLET, DELAYED ACTION, ENTERIC COATED16.24 MG
ORALTABLET, SUSTAINED ACTION70 MG
ORALTABLET, SUSTAINED ACTION, FILM COATED105 MG
SOFT TISSUEINJECTION ADJPH
SOFT TISSUEINJECTION, SUSTAINED ACTION1.35 MG/ML
SUBCUTANEOUSINJECTABLE0.19 %
SUBCUTANEOUSINJECTION0.38 %
SUBCUTANEOUSPOWDER, FOR INJECTION SOLUTION0.54 %
SUBCUTANEOUSPOWDER, FOR INJECTION SOLUTION, LYOPHILIZED0.34 %
SUBCUTANEOUSSOLUTION, INJECTION0.089 %
SUBCUTANEOUSSUSPENSION0.38 %
SUBCUTANEOUSSUSPENSION, INJECTION0.38 %
TOPICALCREAM, EMULSION, SUSTAINED RELEASE0.2 %W/W
TOPICALEMULSION, CREAM0.34 %W/W
TOPICALLOTION1.59 %W/W
TOPICALOINTMENT0.15 %W/W
TOPICALSOLUTION49.78 %W/W
TOPICALSOLUTION2.76 mg/1mL
TOPICALSOLUTION, DROPS0.27 %W/V
TOPICALSPONGE NA
URETHRALINJECTION2 %

© 2021 FDA.report
This site is not affiliated with or endorsed by the FDA.